Duke's Califf to be No. 2 at FDA

ODAC unanimously upholds MRD as early endpoint across all settings in multiple myeloma

In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.

April 26, 2024

Vol.50 No.17

By Jacquelyn Cobb

Conversation with The Cancer Letter

Clearing the path for MRD as early endpoint in multiple myeloma

Sylvester’s C. Ola Landgren: “I was convinced that this is really the way to go”

Black patients with multiple myeloma aren’t getting autoHCT as often as others—and the disparity has widened

Black patients are less likely than patients of other races and ethnicities to receive autologous hematopoietic cell transplants for multiple myeloma, according to a study published in the April issue of Clinical Lymphoma, Myeloma, and Leukemia.

April 26, 2024

Vol.50 No.17

By McKenzie Prillaman

Conversation with The Cancer Letter

ARPA-H’s Andrew Carney: Join the AI Cyber Challenge to counter cyberattacks on health systems

Can AI-enabled technology safeguard hospitals, pharmacies, and medical devices from cyberattacks?

April 26, 2024

Vol.50 No.17

By Matthew Bin Han Ong

In the Archives

Paul Grotzinger and Jerry Hanks: Fox Chase pioneers

Fox Chase Cancer Center has contributed two articles to the Cancer History Project, documenting the impact of Paul Grotzinger and Gerald “Jerry” Hanks.

April 26, 2024

Vol.50 No.17